Cohort of Patients With Chronic Myelomonocytic Leukemia
MYELOMONO-3
2 other identifiers
observational
5,000
1 country
24
Brief Summary
A prospective, non-interventional study involving the collection of biological samples with associated anonymised data. Biological samples will be collected at the time of diagnosis and/or as the disease progresses, with or without treatment, always in conjunction with tests scheduled as part of routine care or within the context of a clinical trial.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2026
Longer than P75 for all trials
24 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 27, 2026
CompletedFirst Posted
Study publicly available on registry
April 6, 2026
CompletedStudy Start
First participant enrolled
May 5, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2040
ExpectedStudy Completion
Last participant's last visit for all outcomes
March 1, 2040
May 19, 2026
May 1, 2026
13.8 years
March 27, 2026
May 15, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Understanding the pathophysiology of chronic myelomonocytic leukaemia
optimise diagnosis, improve prognostic stratification, identify new treatment options and assess patients' response to proposed treatments through the analysis of blood or bone marrow samples collected as part of routine care or clinical trials
through study completion, an average of 15 years
Study Arms (1)
Cohort of patients with chronic myelomonocytic leukemia
Interventions
Blood samples taken as part of a scheduled assessment within the context of medical care * Standard sample: 2 x 10 mL EDTA tubes * For the initial assessment: 1 x 10 mL dry tube At the request of the research teams: one EDTA tube may be replaced by a heparinised or citrated tube, depending on the planned research. Bone marrow samples, taken during a scheduled myelogram as part of medical care * Myelogram: 1 x 2 mL EDTA tube In exceptional cases, during a scheduled surgical procedure, a tissue sample will be considered in consultation with the surgeon (affected tissue, surrounding healthy tissue).
Eligibility Criteria
Cohort of Patients With Chronic Myelomonocytic Leukemia
You may qualify if:
- Adults aged 18 years and over
- Blood monocytosis ≥ 0.5 × 10⁹/L and ≥ 10% of total white blood cells or
- Confirmed diagnosis of chronic myelomonocytic leukemia
- Regardless of stage (chronic or transformed), and whether or not currently being treated
- Signed informed consent
You may not qualify if:
- Active, uncontrolled infection (particularly hepatitis B, hepatitis C, HIV)
- Refusal informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (24)
CHU Amiens Picardie
Amiens, 80054, France
CHU Angers
Angers, 49933, France
Hôpital Privé Antony
Antony, 92160, France
AP-HP Hôpital Avicenne
Bobigny, 93000, France
Centre Hospitalier Sud Francilien
Corbeil-Essonnes, 91106, France
CHU Grenoble
Grenoble, 38000, France
AP-HP Hôpital Bicêtre
Le Kremlin-Bicêtre, 94270, France
CHRU Lille Hôpital Claude Huriez
Lille, 59037, France
CHU Limoges
Limoges, 87042, France
CHU Nantes
Nantes, 44093, France
CHU Nice Hôpital l'Archet 1
Nice, 06202, France
Groupe Hospitalo-Universitaire Caremeau Institut de Cancérologie du Gard
Nîmes, 30029, France
AP-HP Hôpital Saint-Antoine
Paris, 75012, France
AP-HP Hôpital Cochin
Paris, 75014, France
AP-HP Hôpital Necker
Paris, 75015, France
AP-HP Hôpital Saint-Louis
Paris, 75475, France
CHU Bordeaux
Pessac, 33604, France
CHU Poitiers
Poitiers, 86000, France
Centre Henri Becquerel
Rouen, 76038, France
Centre Hospitalier Saint-Brieuc Hôpital Yves Le Foll
Saint-Brieuc, 22000, France
CHU Toulouse
Toulouse, 31059, France
CHU Tours
Tours, 37044, France
CHRU Nancy Brabois
Vandœuvre-lès-Nancy, 54511, France
Gustave Roussy
Villejuif, 94805, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 27, 2026
First Posted
April 6, 2026
Study Start
May 5, 2026
Primary Completion (Estimated)
March 1, 2040
Study Completion (Estimated)
March 1, 2040
Last Updated
May 19, 2026
Record last verified: 2026-05